CHO Pharma, Inc. (6586.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$105.00 (-2.33%) as of
Key statistics
- Market cap
- 22.47B
- EPS (TTM)
- -1.26
- Dividend yield
- 0.00%
- 52-week range
- 22.75 – 148.50
- Beta
- 0.94
- Revenue (TTM)
- 1.71M
- Profit margin
- 0.00%
- Volume
- 332.98k
About CHO Pharma, Inc.
CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which is in Phase I/IIa clinical trials for the treatment of refractory non-Hodgkin lymphoma; CHO-A04, a humanized monoclonal antibody, which is in phase I clinical trials to treat various tumor and cancer stem cells; and CHO-V08 vaccines for the treatment of klebsiella pneumonia. Further, it develops CHO-H02 that is in preclinical stage to target solid tumors, including breast, bladder, pancreatic, ovarian, and gastric cancers; and CHO-H03, an antibody drug that is in pre-clinical development stage indicated for inflammatory conditions in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease. CHO Pharma, Inc. was founded in 2012 and is based in Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.